Royalty Pharma (RPRX) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Royalty Pharma (RPRX) has outperformed Zoetis (ZTS) over the past year, gaining 56.1% versus a loss of 49.1%. Over five years, RPRX leads with a +46.4% price change compared with -63.9% for ZTS. Royalty Pharma is the larger company by market cap ($32.97 billion vs $30.77 billion), about 1.1 times the size.
On valuation, Royalty Pharma trades at a lower forward P/E (9.9x vs 11.4x for Zoetis). Zoetis offers the higher dividend yield (2.77% vs 1.60%). Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus 28.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RPRX | ZTS |
|---|---|---|
| Share price | $57.05 | $74.46 |
| Market cap | $32.97B | $30.77B |
| 1-day change | +1.49% | +1.88% |
| YTD return | +45.47% | -41.92% |
| 1-year return | +56.05% | -49.07% |
| 5-year return | +46.42% | -63.86% |
| P/E ratio (TTM) | 30.35 | 12.25 |
| Forward P/E | 9.95 | 11.38 |
| EPS (TTM) | $1.88 | $6.08 |
| Dividend yield | 1.60% | 2.77% |
| Annual dividend | $0.91 | $2.06 |
| Revenue (latest FY) | $2.38B | $9.47B |
| Revenue growth (YoY) | +5.06% | +2.28% |
| Net income (latest FY) | $770.95M | $2.67B |
| Gross margin | — | 71.84% |
| Operating margin | 65.58% | — |
| Net margin | 32.42% | 28.23% |
| 52-week high | $64.38 | $148.30 |
| 52-week low | $35.23 | $68.77 |
| Distance from 52-week high | -11.39% | -49.79% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +14.60% | +28.94% |
| Average volume | 2.92M | 5.46M |
| Shares outstanding | 445.28M | 413.22M |
| Employees | 100 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RPRX has outperformed ZTS by 105.1 percentage points over the past year.
- Royalty Pharma trades at a higher earnings multiple (30.3x vs 12.2x trailing P/E).
- Zoetis offers a meaningfully higher dividend yield (2.77% vs 1.60%).
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
RPRX vs ZTS FAQ
Which is bigger, Royalty Pharma or Zoetis?
Royalty Pharma (RPRX) is larger, with a market capitalization of $32.97B compared with $30.77B for Zoetis (ZTS).
Which stock has performed better over the past year, RPRX or ZTS?
RPRX returned +56.05% over the past 12 months, compared with -49.07% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, RPRX or ZTS?
ZTS has the lower trailing P/E at 12.2, versus 30.3 for RPRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Royalty Pharma or Zoetis?
Zoetis has the higher yield at 2.77%, compared with 1.60% for Royalty Pharma.
Are Royalty Pharma and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.